ELSI Friday Forum

Friday, February 13, 12:00pm - 1:00pm (EST)

Title: Just CRISPR: Is interventional genetics for rare diseases scalable?
ELSI Friday Forum | February 13th, 2026 | 12PM ET/ 9AM PT via Zoom

In 2025, KJ Muldoon was the first patient to be treated for a life-threatening genetic disorder with gene editing therapy. KJ received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency (CPS1) as a neonate, and received treatment when he was 7 months old, under Expanded Access approval from the FDA. Because rare diseases such as CPS1 cannot be evaluated in traditional clinical trials, regulators are considering new pathways to approval for broader populations. However, as investigators scale up to n-of-few or larger trials, new ethical issues must be considered: What data should be shared to generate the most useful, generalizable knowledge? What expertise and manufacturing infrastructure is necessary to conduct these trials safely under immense time pressure? How can conflicts of interests be mitigated? What do families require to trust interventional genetic therapies? And how should balancing risks and benefits guide patient selection as more knowledge about safety and effectiveness is gained?.

Speakers: Kiran Musunuru, MD, PhD, MPH, PhD; Tania Simoncelli, MA
Moderator: Marsha Michie, PhD

Time shown in-05:00America, New York

Link:

Friday, February 13, 12:00pm - 1:00pm (EST)

Please fill out the information below to register for the event.

Name

Yes

Is this your first time attending an ELSI Friday Forum?

Which of the following best describes your field or occupation?

Confirmed

We've sent a confirmation email to your email address. Be sure to check your junk folder in case you haven't received the confirmation.

Add to Calendar2026/02/13 12:00:002026/02/13 13:00:00America/New_YorkELSI Friday ForumMeeting ID: 890 9844 4304
Passcode: 488218

---

Title: Just CRISPR: Is interventional genetics for rare diseases scalable?
ELSI Friday Forum | February 13th, 2026 | 12PM ET/ 9AM PT via Zoom

In 2025, KJ Muldoon was the first patient to be treated for a life-threatening genetic disorder with gene editing therapy. KJ received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency (CPS1) as a neonate, and received treatment when he was 7 months old, under Expanded Access approval from the FDA. Because rare diseases such as CPS1 cannot be evaluated in traditional clinical trials, regulators are considering new pathways to approval for broader populations. However, as investigators scale up to n-of-few or larger trials, new ethical issues must be considered: What data should be shared to generate the most useful, generalizable knowledge? What expertise and manufacturing infrastructure is necessary to conduct these trials safely under immense time pressure? How can conflicts of interests be mitigated? What do families require to trust interventional genetic therapies? And how should balancing risks and benefits guide patient selection as more knowledge about safety and effectiveness is gained?.

Speakers: Kiran Musunuru, MD, PhD, MPH, PhD; Tania Simoncelli, MA
Moderator: Marsha Michie, PhD

https://us06web.zoom.us/j/89098444304?pwd=bFYBPeXi0eCMgOQXCnkNc7kBHkgrWG.1 CERA | ELSIhubinfo@elsihub.orgfalse30

Confirmed

We've sent a confirmation email to your email address. Be sure to check your junk folder in case you haven't received the confirmation.

Thank you!

Your changes have been saved. Thanks for keeping us updated.

CERA | ELSIhub, info@elsihub.org